FilingSEC EDGAR6-K
Tiziana Life Sciences presents Phase 2a study poster for foralumab at ALS Nexus
· SEC accepted
StagePhase 2a
Filing content
Tiziana Life Sciences presented the study design and scientific rationale for its Phase 2a BANYAN trial of intranasal foralumab for ALS at the ALS Nexus 2026 conference.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…